BioNTech has announced an all-stock acquisition of CureVac, valued at approximately $1.25 billion, aiming to consolidate its position in mRNA vaccine technology and oncology. The deal offers CureVac shareholders a 55% premium and is expected to close later this year. BioNTech highlights the acquisition of CureVac's advanced research and manufacturing capabilities in Tübingen, Germany, rather than its current pipeline. This move follows ongoing patent disputes and reflects BioNTech's broader strategy to expand its immunotherapy portfolio and regulatory reach.